Quintiles is expanding its reach in personalized medicine, forming a new company that will conduct biomarker research and development in cancer. The company, Oxford Cancer Biomarkers, is based on technology developed at the University of Oxford. CancerNav is a proprietary DNA and protein-based test technology platform that can quickly identify biomarkers that can be used […]
Quintiles is expanding its healthcare social media reach with the launch of a new digital business unit that will help the company recruit patients for clinical trials. The new Digital Patient unit builds on the clinical research organization’s existing services for clinical trial recruitment and brings together two of Quintiles’ patient-facing online sites: MediGuard.org […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Quintiles is expanding its reach in the Asia-Pacific region with the launch of Kun Tuo, a new contract research organization in China. The new CRO will serve pharmaceutical companies in China as well as multinational biopharma companies that have operations in the country. Kun Tuo will also tap the resources of Durham, North Carolina-based Quintiles, […]
Samsung Biologics, the drug manufacturing business that a South Korean conglomerate formed earlier this year with the help of pharmaceutical services firm Quintiles, is partnering on a $300 million initiative with Biogen Idec (NASDAQ:BIIB). The joint venture, which will be based in South Korea, will develop, manufacture and market biosimilars, biological products that are similar […]
Following a flurry of Quintiles acquisitions, the pharmaceutical services company now has news of a sale. Quintiles has sold its minority stake in drug commercialization joint venture Invida six years after forming the Asia Pacific-focused company with two other strategic investors. Menarini Group, a private Italian pharmaceutical company, has acquired all of Singapore-based Invida. Financial […]
Quintiles‘ M&A activity continues as the company announced it will acquire clinical research organization Advion BioServices — Quintiles’ third deal in the last week. Advion provides bioanalytical lab services that help pharmaceutical companies understand how a drug performs in the body. A definitive agreement to acquire the Ithaca, New York-based CRO was signed today. Financial […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Quintiles announced its second strategic acquisition of the day, a deal to buy late phase pharmaceutical research firm Outcome Sciences. Durham, North Carolina-based Quintiles earlier today announced acquisitions of pharmaceutical marketing and commercialization firm VCG & Associates and its subsidiary VCG BIO. Outcome Sciences, based in Cambridge, Massachusetts, conducts late-stage and post-marketing research on drugs. […]
Quintiles has acquired pharmaceutical commercialization and marketing firm VCG & Associates and its subsidiary, VCG Bio, in a move to bolster the company’s drug capabilities to bring new drugs to market. Durham, North Carolina based Quintiles, already the largest clinical research organization or CRO, has been taking steps to build its drug commercialization offerings in […]
Quintiles has named a former executive from medical devices company Teleflex (NYSE:TFX) to a top financial position at the pharmaceutical services firm. Charles Williams will serve as worldwide controller for Durham, North Carolina-based Quintiles, reporting directly to the company’s CFO Kevin Gordon. Williams had served as corporate controller and chief accounting officer for Teleflex, a […]
Quintiles has a new chief medical and scientific officer. The Durham, North Carolina-based clinical research organization named Dr. Jeffrey Spaeder to the position on Wednesday. He succeeds Dr. Oren Cohen, who had served as the company’s chief medical officer since 2004. Cohen now leads Quintiles phase 1 clinical research business. Spaeder comes to Quintiles from […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Quintiles is putting money into a Swiss pharmaceutical company that has drug candidates for Alzheimer’s disease and type 2 diabetes approaching clinical trials this year. Durham, North Carolina-based Quintiles has struck up a strategic alliance with Swiss drug development company Kareus Therapeutics, which is readying for clinical trials on the two compounds. Financial terms were […]
Quintiles wanted to find out what healthcare stakeholders think about the industry, so the company did the natural thing: It conducted a survey. For two months this winter, a company hired by Quintiles called up biopharmaceutical executives, managed care executives, doctors and patients. Is it any surprise that these constituencies were not on the same […]
Quintiles is always part of conversations about the direction of the clinical research industry. The company is now making sure that it gets a handle on less formal conversations in social media. Durham, North Carolina-based Quintiles has come up with social media guidelines for employees. Quintiles is the CRO industry’s largest provider, with more than […]
Quintiles is partnering with British genomics testing company Population Genetics Technologies in a move that broadens the clinical research organization’s capability to bring genetic testing and analysis into the clinical development of drugs. Durham, North Carolina-based Quintiles said it will work with PGT to find opportunities for large-scale genomic analysis, tests that use samples from […]
Quintiles is resuming its plans to raise more than $2 billion in bank financing. The Durham, North Carolina, clinical research organization announced late Tuesday that it would enter into a new $2.2 billion credit facility, with proceeds from the borrowed money being used to refinance $1.7 billion in existing debt, including an offer to buy […]